Cargando…
Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy
Obesity and type 2 diabetes mellitus (T2D) represent important comorbidities of the metabolic syndrome, which are associated with non-alcoholic fatty liver disease (NAFLD)-related hepatic fibrosis. In total, 160 morbidly obese patients—81 following a low-calorie formula diet (LCD) program and 79 und...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999703/ https://www.ncbi.nlm.nih.gov/pubmed/35407364 http://dx.doi.org/10.3390/jcm11071756 |
_version_ | 1784685252469325824 |
---|---|
author | Schmid, Andreas Arians, Miriam Karrasch, Thomas Pons-Kühnemann, Jörn Schäffler, Andreas Roderfeld, Martin Roeb, Elke |
author_facet | Schmid, Andreas Arians, Miriam Karrasch, Thomas Pons-Kühnemann, Jörn Schäffler, Andreas Roderfeld, Martin Roeb, Elke |
author_sort | Schmid, Andreas |
collection | PubMed |
description | Obesity and type 2 diabetes mellitus (T2D) represent important comorbidities of the metabolic syndrome, which are associated with non-alcoholic fatty liver disease (NAFLD)-related hepatic fibrosis. In total, 160 morbidly obese patients—81 following a low-calorie formula diet (LCD) program and 79 undergoing bariatric surgery (Roux-en-Y gastric bypass, RYGB)—were examined for anthropometric and metabolic parameters at base-line and during 12 months of weight loss, focusing on a putative co-regulation of T2D parameters and liver fibrosis risk. High NAFLD fibrosis scores (NFS) before intervention were associated with elevated HbA1c levels and T2D. Loss of weight and body fat percentage (BFL) were associated with improved glucose and lipid metabolism and reduced risk of NAFLD-related fibrosis, with particularly beneficial effects by RYGB. Both T2D improvement and NFS decrease were positively associated with high BFL. A highly significant correlation of NFS reduction with BFL was restricted to male patients while being absent in females, accompanied by generally higher BFL in men. Overall, the data display the relation of BFL, T2D improvement, and reduced NAFLD-related fibrosis risk during weight loss in morbidly obese individuals induced by diet or RYGB. Furthermore, our data suggest a considerable sexual dimorphism concerning the correlation of fat loss and improved risk of liver fibrosis. |
format | Online Article Text |
id | pubmed-8999703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89997032022-04-12 Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy Schmid, Andreas Arians, Miriam Karrasch, Thomas Pons-Kühnemann, Jörn Schäffler, Andreas Roderfeld, Martin Roeb, Elke J Clin Med Article Obesity and type 2 diabetes mellitus (T2D) represent important comorbidities of the metabolic syndrome, which are associated with non-alcoholic fatty liver disease (NAFLD)-related hepatic fibrosis. In total, 160 morbidly obese patients—81 following a low-calorie formula diet (LCD) program and 79 undergoing bariatric surgery (Roux-en-Y gastric bypass, RYGB)—were examined for anthropometric and metabolic parameters at base-line and during 12 months of weight loss, focusing on a putative co-regulation of T2D parameters and liver fibrosis risk. High NAFLD fibrosis scores (NFS) before intervention were associated with elevated HbA1c levels and T2D. Loss of weight and body fat percentage (BFL) were associated with improved glucose and lipid metabolism and reduced risk of NAFLD-related fibrosis, with particularly beneficial effects by RYGB. Both T2D improvement and NFS decrease were positively associated with high BFL. A highly significant correlation of NFS reduction with BFL was restricted to male patients while being absent in females, accompanied by generally higher BFL in men. Overall, the data display the relation of BFL, T2D improvement, and reduced NAFLD-related fibrosis risk during weight loss in morbidly obese individuals induced by diet or RYGB. Furthermore, our data suggest a considerable sexual dimorphism concerning the correlation of fat loss and improved risk of liver fibrosis. MDPI 2022-03-22 /pmc/articles/PMC8999703/ /pubmed/35407364 http://dx.doi.org/10.3390/jcm11071756 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmid, Andreas Arians, Miriam Karrasch, Thomas Pons-Kühnemann, Jörn Schäffler, Andreas Roderfeld, Martin Roeb, Elke Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy |
title | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy |
title_full | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy |
title_fullStr | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy |
title_full_unstemmed | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy |
title_short | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy |
title_sort | improvement of type 2 diabetes mellitus and attenuation of nafld are associated with the success of obesity therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999703/ https://www.ncbi.nlm.nih.gov/pubmed/35407364 http://dx.doi.org/10.3390/jcm11071756 |
work_keys_str_mv | AT schmidandreas improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy AT ariansmiriam improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy AT karraschthomas improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy AT ponskuhnemannjorn improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy AT schafflerandreas improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy AT roderfeldmartin improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy AT roebelke improvementoftype2diabetesmellitusandattenuationofnafldareassociatedwiththesuccessofobesitytherapy |